Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Journal of Thrombosis and Haemostasis : JTH|September 17, 2021
The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort studyAnthony Maraveyas, Noémie Kraaijpoel, George Bozas, et al.
Current Medical Research and Opinion|January 11, 2023
A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UKAlexander T Cohen, Gary Benson, Charlotte A Bradbury, et al.
Health Technology Assessment (Winchester, England)|October 23, 2015
A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT)Simon I Noble, Annmarie Nelson, David Fitzmaurice, et al.
Plos Medicine|August 25, 2025
Shared decision-making and deprescribing to support anti-thrombotic therapy (dis)continuance for persons living with cancer in their last phase of life: A realist synthesisJustin Jagosh, Mark Pearson, Sarah Greenley, et al.
Lancet (London, England)|July 17, 2007
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trialMatthew T Seymour, Timothy S Maughan, Jonathan A Ledermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2018
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)Annie M Young, Andrea Marshall, Jenny Thirlwall, et al.
British Journal of Cancer|June 22, 2018
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trialAlison C Backen, Andre Lopes, Harpreet Wasan, et al.
The Lancet. Oncology|July 17, 2015
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trialJuan W Valle, Harpreet Wasan, Andre Lopes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2019
Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort StudyNoémie Kraaijpoel, Suzanne M Bleker, Guy Meyer, et al.
The Lancet. Oncology|April 2, 2021
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trialAngela Lamarca, Daniel H Palmer, Harpreet Singh Wasan, et al.
Pageof 12